Demand is increasing from regulators and payers as they struggle to manage budget constraints and provide access to new therapies
Register to receive a recording of the webinar and get a deeper understanding of the use of early economic models to inform key strategic decisions.
Health economic models are required to demonstrate product value and support reimbursement submissions; however, early economic models can also be used to inform clinical development decisions, develop HEOR and real world evidence (RWE) generation planning and support early pricing and market access discussions.
Key insights include:
- Types of early economic models and why are they important
- Guidelines on their development and the selection of data sources
- Case-examples of use in evidence strategy generation
- How early economic models are used to identify evidence gaps
Victoria Paly, MHS
Senior Health Economist, ICON Commercialisation & Outcomes
Victoria has worked in HEOR for over 6 years supporting the development of effective value propositions for pharmaceutical products. She has extensive experience in retrospective database analysis and economic modelling, including development of cost-effectiveness analyses to support HTA submissions.
Dhvani Shah, MS
Lead Health Economist, ICON Commercialisation and Outcomes
Dhvani Shah has over 8 years of experience in HEOR, and has led numerous evidence generation activities to demonstrate and communicate product value. She is responsible for preparing HEOR evidence and value strategies, developing economic models for HTA submissions and conducting literature reviews and evidence synthesis activities.
This program is intended for professionals from pharmaceutical, biotech, and medical device companies involved in:
- Health Economics & Outcomes Research (HEOR)
- Market Access
- Medical Affairs
- Regulatory Affairs
- Pharmacovigilance & Risk Management